Group 1 - The core viewpoint of the news is that Xinhan New Materials experienced a decline in stock price and significant changes in financing activities on November 11, with a net financing outflow of 21.71 million yuan [1] - As of November 11, Xinhan New Materials had a total financing and securities lending balance of 308 million yuan, which accounts for 3.79% of its market capitalization, indicating a high level of financing [1] - The company reported a revenue of 330 million yuan for the period from January to September 2025, representing a year-on-year growth of 7.99%, and a net profit attributable to shareholders of 51.53 million yuan, up 23.32% year-on-year [2] Group 2 - Xinhan New Materials has distributed a total of 153 million yuan in dividends since its A-share listing, with 113 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders in Xinhan New Materials decreased by 3.55% to 29,900, while the average circulating shares per person increased by 3.68% to 3,672 shares [2]

Group 1 - The core viewpoint of the news is that Xinhan New Materials has shown significant trading activity and financial performance, with a notable increase in stock price and financing activities [1][2]. - On November 6, Xinhan New Materials' stock price increased by 3.31%, with a trading volume of 304 million yuan. The financing buy-in amount was 31.47 million yuan, while the net financing buy-in was 5.74 million yuan [1]. - As of November 6, the total financing and securities lending balance for Xinhan New Materials was 316 million yuan, which represents 3.72% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. Group 2 - As of October 31, the number of shareholders for Xinhan New Materials was 31,000, a decrease of 2.52% from the previous period, while the average circulating shares per person increased by 2.58% to 3,542 shares [2]. - For the period from January to September 2025, Xinhan New Materials achieved a revenue of 330 million yuan, reflecting a year-on-year growth of 7.99%, and a net profit attributable to the parent company of 51.53 million yuan, which is a 23.32% increase year-on-year [2]. - Since its A-share listing, Xinhan New Materials has distributed a total of 153 million yuan in dividends, with 113 million yuan distributed over the past three years [3].

1. Report Industry Investment Rating - No information provided in the given content 2. Core View of the Report - In the first three quarters of 2025, the company achieved an operating income of 330 million yuan, a year - on - year increase of 7.99%, and a net profit of 51.53 million yuan, a year - on - year increase of 23.32%. The company is optimistic about the development of the PEEK industry chain, and the production and market expansion of cosmetic raw material HAP are progressing normally. The company's product毛利率 has rebounded due to increased capacity utilization and decreased raw material prices [25][27][30] 3. Summary According to the Directory 3.1 Research Basic Situation - The research object is Xinhan New Materials, belonging to the chemical raw material industry. The reception time was on October 21, 2025, and the listed company's reception staff included the board secretary Li Xiangfei, the financial director Wang Zhongyan, and the securities affairs representative Ge Mingmin [16] 3.2 Detailed Research Institutions - The research institutions include fund management companies such as Baoying Fund, Chuangjin Hexin Fund, and Xinda Australia Asia Fund; investment companies like Dingtian Investment and Ruiyi Investment; securities companies such as Shenwan Hongyuan and CITIC Construction Investment Securities; other institutions including Marco Polo China Assets and Hongyun Private Equity Fund; and banks such as Ping An Bank [17][18] 3.3 Research Institution Proportion - No information provided in the given content 3.4 Main Content Data - **2025 Q1 - Q3 Brief Analysis**: The company achieved an operating income of 330 million yuan, a year - on - year increase of 7.99%, and a net profit of 51.53 million yuan, a year - on - year increase of 23.32%. The comprehensive gross profit margin and sales net profit margin of products gradually improved. The sales of the main products included 40% of DFBP, 18% of photoinitiators, 22% of cosmetic raw materials, and about 20% of medical and agricultural intermediates [25] - **Question and Answer Session**: - **DFBP**: The product price is adjusted periodically according to raw material prices and other factors and is currently at a low level. The production mainly comes from new capacity, with high capacity utilization and gradually repaired gross profit margin [26] - **PEEK**: It has excellent comprehensive performance, and new attempts in high - end manufacturing fields have added new growth momentum. The company is optimistic about the development of the PEEK industry chain [27][28] - **Cosmetic Raw Material HAP**: The production and market expansion are progressing normally, and the sales volume growth is due to the development of new customers and increased penetration. The product price is adjusted periodically [28] - **Three - Workshop of the Fund - Raising Project**: The equipment is being installed and is expected to be completed by December 2025 [29] - **Reasons for Gross Profit Margin Rebound in Q1 - Q3**: The continuous and stable increase in capacity utilization reduces the fixed cost per unit product, and the raw material price has decreased [30]

Financial Performance - In the first three quarters of 2025, the company achieved a revenue of 330 million CNY, representing a year-on-year growth of 7.99% [2] - The net profit for the same period was 51.53 million CNY, showing a year-on-year increase of 23.32% [2] Product Sales Composition - The sales composition of the company's main products includes: - DFBP: 40% - Photoinitiators: 18% - Cosmetic raw materials: 22% - Agricultural and pharmaceutical intermediates: approximately 20% [3] Product Pricing and Capacity - The pricing of DFBP is influenced by raw material costs and is currently at a low level due to these factors; however, production capacity is increasing, leading to gradual recovery in gross margins [4] - The demand for PEEK is growing due to its excellent properties, with applications in aerospace, medical implants, and high-end manufacturing, indicating a positive industry outlook [5] - The production and market expansion of HAP are progressing normally, with sales growth attributed to new customer acquisition and increased penetration [6] Investment Projects - The progress of the fundraising project for the third workshop (HDO) is ongoing, with equipment installation expected to be completed by December 2025 [7] Margin Improvement Factors - The recovery in product gross margins is primarily due to stable increases in capacity utilization, reduced fixed costs per unit, and a decrease in raw material prices during the first three quarters of 2025 [8]

Report Summary 1. Reported Industry Investment Rating No information provided in the document. 2. Core Viewpoints The report mainly presents the results of a research on Xinhan New Materials, covering the company's basic information, research institutions, and answers to investors' questions about the company's operations, including project progress, cash management, product sales, investment purposes, R & D directions, and the impact of trade protection measures [16][23][28]. 3. Summary by Directory 3.1 Research Basic Situation - Research object: Xinhan New Materials [16] - Industry: Chemical raw materials [16] - Reception time: September 12, 2025 [16] - Listed company reception personnel: Chairman and General Manager Yan Liuxin, Financial Controller Wang Zhongyan, Board Secretary Li Xiangfei, Independent Director Huang Hefa [16] 3.2 Detailed Research Institutions - Institutions: Investors who participated in the company's 2025 semi - annual performance briefing online [19] 3.3 Main Content Data - **Project Progress**: The equipment of the third workshop of the 8000 - ton project is being installed and is expected to reach the intended use state and be put into production in December 2025 [23] - **Cash Management**: The company's cash management is mainly used to purchase cash management products with high safety, good liquidity, and a maximum term of no more than twelve months, such as RMB structured deposits and time deposits [24] - **Foreign Exchange Hedging**: The company did not actually carry out specific foreign exchange hedging business during the reporting period and plans to conduct it within the board - authorized limit according to exchange rate fluctuations [26] - **Product Sales**: The sales of the company's main products such as medical and agricultural intermediates, DFBP, and photoinitiators have all increased to varying degrees [27] - **Investment Purpose**: The company invests in Mingxi Equity Investment Fund and Zhejiang Pengfulong Technology to layout fields related to its main business, achieve industrial synergy and capital appreciation, and strengthen its influence in the special engineering plastics field [28] - **R & D Direction**: The company's main R & D direction is focused on the R & D and process improvement of aromatic ketone core products, including special engineering plastic core raw materials and cosmetic raw materials [28] - **Product Situation**: The penetration rate of the company's HAP product as a cosmetic raw material is gradually increasing, and the HDO production line is under construction. The HDO product can be directly used as a cosmetic raw material with moisturizing and bactericidal effects [30] - **Trade Protection Impact**: The company will closely monitor international market trends, actively explore new international markets, develop new products, and expand the domestic market to reduce the impact of export business risks [30] - **Medical and Agricultural Intermediate Business**: The company's medical and agricultural intermediate products have a large variety. After the new workshop of the 8000 - ton project is put into operation, new customers and markets are developed, resulting in rapid growth [30]

Group 1: Company Operations and Developments - The construction of the third workshop for the 8000-ton project is currently underway, with equipment installation in progress and expected to be operational by December 2025 [2] - The company is focusing its cash management on high-security, high-liquidity products, including structured deposits and time deposits, with a maximum term of twelve months [2] - The company has not yet implemented specific foreign exchange hedging activities but is monitoring exchange rate fluctuations closely [3] Group 2: Product Performance and Market Strategy - Sales of key products such as pharmaceutical intermediates, DFBP, and photoinitiators have shown varying degrees of growth [3] - Investments in Mingxi Equity Investment Fund and Zhejiang Pengfulong Technology aim to enhance synergy with the company's main business and strengthen its influence in the specialty engineering plastics sector [3] - The company is concentrating its R&D efforts on core products related to aromatic ketones and process improvements, with specific advancements to be disclosed in the annual report [3] Group 3: Market Challenges and Adaptations - The company is actively exploring new international markets to mitigate risks associated with U.S. tariffs and trade protection measures affecting exports [4] - The pharmaceutical intermediates segment is expected to become a significant growth driver following the new workshop's production capacity expansion [4]

Group 1: Zhongji United - In the first half of 2025, Zhongji United achieved operating revenue of 818 million yuan, a year-on-year increase of 43.52%, and a net profit of 262 million yuan, up 86.61% [1] - The growth in performance is attributed to the rapid development of the wind power industry, with both domestic and international revenues increasing and new orders continuing to rise steadily [1] - The gross profit margin improved to 50.15%, mainly due to an increase in export revenue, changes in the domestic product structure, and a higher proportion of revenue from the US market [1] Group 2: Xinhang New Materials - In the first half of 2025, Xinhang New Materials reported operating revenue of 229 million yuan, a year-on-year increase of 9.66%, and a net profit of 35.29 million yuan, up 20.40% [2] - The sales volume of the main products increased by approximately 30%, with DFBP, HP, and photoinitiators rising by around 25%, and pharmaceutical intermediates increasing by over 50% [2] - The recovery in gross profit margin is attributed to improved capacity utilization and a decrease in fixed cost allocation [2] Group 3: Tianfu Communication - In the first half of 2025, Tianfu Communication achieved operating revenue of 2.456 billion yuan, a year-on-year increase of 57.84%, and a net profit of 899 million yuan, up 37.46% [3] - The growth in active business is primarily due to the increased delivery of high-speed active products, with the company continuously expanding its customer base [3] - The gross profit margin decreased due to changes in product structure, with a higher proportion of revenue coming from active products [3]

Group 1: Xinhang New Materials (新瀚新材) - In the first half of 2025, Xinhang New Materials achieved revenue of 229 million yuan, a year-on-year increase of 9.66%, and a net profit of 35.29 million yuan, up 20.40% [1] - The sales volume of the company's main products increased by approximately 30%, with DFBP, HP, and photoinitiators growing by around 25%, and pharmaceutical intermediates sales rising by over 50% [1] - The growth in DFBP sales is attributed to the exploration of new application fields for PEEK, leading to an increase in new customer orders [1] Group 2: Tianfu Communication (天孚通信) - In the first half of 2025, Tianfu Communication reported revenue of 2.456 billion yuan, a year-on-year increase of 57.84%, and a net profit of 899 million yuan, up 37.46% [2] - The growth in active business is primarily driven by the increased delivery of high-speed active products, with the company continuously expanding its customer base [2] - The gross margin decreased due to changes in product structure, with a higher proportion of revenue coming from active products [2] Group 3: Donghai Fund (东海基金) - Donghai Fund, established in 2013, currently manages a total asset scale of 28.42 billion yuan, ranking 105th out of 210 in the public fund management industry [3] - The fund has 47 public funds under management, ranking 107th out of 210, and has 6 public fund managers, ranking 135th out of 210 [3] - The best-performing public fund product in the past year is the Donghai Digital Economy Mixed Fund A, with a latest net value of 1.19 and a growth of 53.85% over the past year [3]

1. Report Industry Investment Rating - No information provided in the given content. 2. Report's Core View - In the first half of 2025, the company achieved an operating income of 229 million yuan, a year - on - year increase of 9.66%, and a net profit of 35.29 million yuan, a year - on - year increase of 20.40%. The company is optimistic about the development of the PEEK industry chain, and the market prospects of HAP and HDO in cosmetics raw materials are good. The company's product sales volume and gross profit margin have increased, mainly due to capacity improvement [24]. 3. Summary According to Relevant Catalogs 3.1 Research Basic Situation - Research object: New Han New Materials; Industry: Chemical raw materials; Reception time: August 26, 2025; Listed company reception personnel: Board Secretary Li Xiangfei, Securities Affairs Representative Ge Mingmin, and Financial Controller Wang Zhongyan [16]. 3.2 Detailed Research Institutions - Fund management companies: Harvest Fund (represented by Xu Heyang), Donghai Fund (represented by Zhang Yuantao), CITIC Prudential Fund (represented by Yao Sizhou), Jianxin Fund (represented by Wu Angda), Chunhou Fund (represented by Tian Wentian) [17]. - Investment companies: Shanghai Xishirun Investment (represented by Liu Chongli), Bissell (Shanghai) Investment (represented by Luo Hongyong), Shanghai Jisheng Investment (represented by Liu Qinglin) [17]. - Securities companies: Nanjing Securities (represented by Gu Shiyuan), Shenwan Hongyuan (represented by Li Shaocheng) [17]. - Others: Zhengyuan Private Fund (represented by Liu Jiasuo) [17]. 3.3 Main Content Data - **2025 Semi - annual Brief Analysis**: The company's operating income in the first half of 2025 was 229 million yuan, a year - on - year increase of 9.66%, and the net profit was 35.29 million yuan, a year - on - year increase of 20.40%. The comprehensive gross profit margin and sales net profit margin improved for two consecutive quarters, reaching 27% and 15.41% respectively. The sales volume of the company's main products increased by about 30%, among which the sales volume of DFBP, HAP, and photoinitiators increased by about 25%, and the sales volume of medical and agricultural intermediates increased by more than 50% [24]. - **Question and Answer Session**: - **DFBP sales growth reason**: Due to the continuous exploration of new application fields of PEEK, the number of new customers of PEEK has increased in the past two years. The company has maintained stable cooperation with old customers, and the orders of individual new customers have also increased [24]. - **PEEK industry prospects**: PEEK has excellent comprehensive performance, and its new attempts in fields such as aerospace, human implants, high - end manufacturing, low - altitude aircraft, and robots have added new growth momentum to the market. The company is optimistic about the development of the PEEK industry chain [24][25]. - **Market prospects of HAP and HDO in 2025**: The company's HAP product is mainly used in high - end creams and masks of well - known brands, and the use cases of some new cosmetic categories and new domestic and foreign brands are increasing. The HDO product can be directly used as a cosmetic raw material, with good moisturizing and bactericidal effects, and is used as a new type of preservative additive similar to HAP, targeting the same customer group as HAP [25]. - **Reason for the increase in the sales volume of pharmaceutical intermediates in the first half of 2025**: After the new workshop of the 8,000 - ton project was put into production, the company's production capacity was sufficient to support the development of new customers and markets for this type of product [26]. - **Factors for the recovery of the company's product gross profit margin in the first half of the year**: The main reason is the stable increase in the company's capacity utilization rate, and the fixed cost per unit product has decreased [26].

Core Insights - The company reported strong revenue and profit growth in the first half of 2025, driven by increasing demand for PEEK materials and a robust performance across its four main business segments [1][2][3] Business Performance - The company achieved a revenue of 229 million yuan, a year-on-year increase of 9.66%, and a net profit of 35.29 million yuan, up 20.40% [2] - The core specialty engineering plastics segment generated revenue of 97.03 million yuan, reflecting a growth of 5.54%, with a gross profit margin of 32.3%, an increase of 7.61 percentage points [2][3] - The light initiators and agricultural intermediates businesses also performed well, with revenues of 38.36 million yuan and 46.39 million yuan, representing year-on-year growth of 11.94% and 38.73%, respectively [3][4] Market Trends - The demand for PEEK materials is expected to grow significantly, with projections indicating an increase from 2,334 tons in 2022 to 5,079 tons by 2027, corresponding to a compound annual growth rate of approximately 16.8% [3] - The company has established stable partnerships with key clients in the PEEK industry, enhancing its competitive position [3] Technological Innovation - The company emphasizes technological innovation as a core driver of its sustained growth, holding 29 invention patents and 21 utility model patents [6][7] - The company has been recognized as a high-tech enterprise and has received various industry accolades, reinforcing its market credibility [6] Production Capacity and Environmental Focus - The company is expanding its production capacity with a new annual capacity of 2,500 tons of DFBP, which will enhance its market competitiveness [3][7] - The company is committed to green manufacturing and has implemented new technologies to reduce emissions and improve production efficiency [7] Shareholder Returns - The company plans to distribute cash dividends of 1.00 yuan per 10 shares to shareholders, reflecting its commitment to shareholder returns and strong profitability [4]